What Reliance Life Sciences does

Reliance Life Sciences Private Limited (RLS) is a privately held, integrated biopharmaceutical company incorporated in 2001 as a wholly-owned subsidiary of Reliance Industries Limited (RIL), the Mukesh Ambani-led conglomerate. Headquartered at the Dhirubhai Ambani Life Sciences Centre in Navi Mumbai, Maharashtra, the company operates across seven business segments: plasma proteins, biosimilars, specialty pharmaceuticals, clinical research services, regenerative medicine and cell therapy, cord blood repository (stem cell banking), and molecular diagnostics, with an additional Covid-19 RT-PCR testing service approved by the Indian Council of Medical Research.

The company's core technology stack is built around biosimilar development and manufacturing, anchored by a portfolio of seven approved biosimilars including AdaliRel (adalimumab), TrastuRel (trastuzumab), BevaciRel (bevacizumab), RituxiRel (rituximab), SomatoRel (somatropin), PegReligrast (pegfilgrastim), and DarbeRel (darbepoetin alfa), each supported by peer-reviewed comparative clinical studies. Specialty pharmaceuticals include MIRel (reteplase), Relipoietin (erythropoietin), and Reliseal (fibrin sealant). Manufacturing is anchored by a US FDA-approved Navi Mumbai facility (January 2016), with additional quality credentials including CAP laboratory accreditation (2007). The company also operates India's first private breast cancer genomics portal (launched 2008) and a Covid-19 RT-PCR testing service validated against Kasturba Hospital Mumbai at 100% concordance.

Reliance Life Sciences generates revenue through a B2B enterprise model combining direct field sales, regional offices across 8 Indian cities, licensing agreements with pharmaceutical distributors (notably Torrent Pharma for biosimilar distribution), and international partnerships (Sri Lanka government for plasma protein manufacturing; Belarus-Cipla-Academpharm joint research center). Customer segments span healthcare providers and hospitals, pharmaceutical companies, government healthcare programs, diagnostic laboratories, and expectant parents (cord blood banking). The company employs 501-1000 staff and was allocated Rs 2,500 crore (~USD 300M) in additional investment according to September 2022 Times of India reports, signaling a major scale-up phase coinciding with the global biosimilar wave as 118 biologics lose US patent protection between 2025 and 2034.

Name

Reliance Life Sciences

Legal name

Reliance Life Sciences Private Limited

Website

https://rellife.com

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Reliance Life Sciences is an integrated biopharmaceutical company developing biosimilars, plasma proteins, specialty pharmaceuticals, clinical research services, regenerative medicine, cord blood banking, and molecular diagnostics for hospitals, pharmaceutical companies, and government healthcare programs across India.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Oncology Biosimilars (HLAAAHAG)

akta.pro secondary industry

Post-Approval Clinical Development (Phase IV & Lifecycle Management) (HLAIALAJ)

Keywords

• Biosimilar development
• Plasma protein therapeutics
• Clinical research services
• Regenerative medicine
• Molecular diagnostics

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Biosimilars: Development and commercialization of biosimilar products including monoclonal antibodies, growth factors, and other biologics for cancer, autoimmune diseases, and other therapeutic areas. Products include TrastuRel (trastuzumab), BevaciRel (bevacizumab), AdaliRel (adalimumab), RituxiRel (rituximab), and others.
2. Plasma Proteins: Manufacturing and sale of plasma-derived proteins including human albumin, coagulation factors, and immunoglobulins for therapeutic use.
3. Clinical Research Services: Full-service clinical research offerings for drug development including Phase I-IV clinical trials, bioequivalence studies, and regulatory support for pharmaceutical companies.
4. Specialty Pharmaceuticals: Development and sale of specialty pharmaceutical products including novel drug formulations and specialty injectable therapies.
5. Diagnostics: Molecular diagnostics services including DNA-based testing, COVID-19 RT-PCR testing, and molecular medicine research services.
6. Cord Blood Repository: Stem cell banking services through cord blood collection, processing, and storage for future therapeutic use.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Reliance Life Sciences is an integrated biopharmaceutical company that develops, manufactures, and commercializes biosimilars, plasma-derived proteins, and specialty pharmaceuticals. The company also provides clinical research services (Phase I-IV trials, bioequivalence studies), regenerative medicine and stem cell therapies, cord blood banking, and molecular diagnostics including RT-PCR Covid-19 testing.

Product overview

Reliance Life Sciences is an integrated biopharmaceutical company with a diversified portfolio organized into seven business segments: Plasma Proteins (plasma-derived therapeutics), Biosimilars (monoclonal antibodies and growth factors including AdaliRel®, TrastuRel®, BevaciRel®, RituxiRel®, SomatoRel®, PegReligrast®, and DarbeRel®), Pharmaceuticals (specialty drugs including MIRel®, Relipoietin®, and Reliseal®), Clinical Research Services (Phase I-IV trial services), Regenerative Medicine (cell therapies), Cord Blood Repository (stem cell banking), and Diagnostics (molecular medicine and DNA-based testing). The company also operates a Covid-19 testing service. The product portfolio spans biosimilar biologics for oncology, autoimmune diseases, and supportive care, alongside specialty pharmaceuticals and diagnostic services, unified under an integrated biopharmaceutical business model.

Differentiator

Problem solved

Functional benefit

Brands

• SomatoRel® (Somatropin): Biosimilar somatropin product
• Reliseal® (Fibrin Sealant)
• PegReligrast® (Pegfilgrastim)
• AdaliRel® (Adalimumab)
• DarbeRel® (Darbepoetin)
• TrastuRel® (Trastuzumab)
• BevaciRel® (Bevacizumab)
• MIRel® (Reteplase)
• RituxiRel® (Rituximab)
• Relipoietin® (Erythropoietin)

Products and services

• SomatoRel (Somatropin) First indigenous biosimilar somatropin (human growth hormone) used for growth disorders, supported by a published comparative clinical study.
• PegReligrast (Pegfilgrastim) Biosimilar pegfilgrastim indicated for chemotherapy-induced neutropenia (CIN), backed by a randomized multicentric double-blind comparative clinical study published in 2018.
• AdaliRel (Adalimumab) Biosimilar adalimumab for rheumatoid arthritis, supported by a prospective randomized double-blind comparative clinical study published in the Indian Journal of Rheumatology (2018).
• TrastuRel (Trastuzumab) Biosimilar trastuzumab for HER2 overexpressing metastatic breast cancer, with Phase III clinical study published in the Indian Journal of Cancer (2017).
• BevaciRel (Bevacizumab) Biosimilar bevacizumab for metastatic colorectal cancer, supported by a comparative pharmacokinetics and efficacy study published in the Indian Journal of Cancer (2017).
• RituxiRel (Rituximab) Biosimilar rituximab for non-Hodgkin's lymphoma, supported by a Phase III multicentric clinical study published in the Asian Journal of Oncology (2017).
• DarbeRel (Darbepoetin) Biosimilar darbepoetin alfa for anemia associated with chronic kidney disease, supported by a comparative efficacy and safety study published in the Indian Journal of Transplantation (2018).
• MIRel (Reteplase) Reteplase thrombolytic agent for ST-elevation myocardial infarction (STEMI), supported by the TRIME study published in the Indian Medical Gazette (2017).
• Relipoietin (Erythropoietin) Recombinant human erythropoietin for anemia in chronic kidney disease patients, supported by a once-weekly administration study published in the Indian Medical Gazette (2011).
• Reliseal (Fibrin Sealant) Fibrin sealant used in post-catheterization pseudo-aneurysm treatment, supported by a case study published in the International Journal of Current Research (2019).
• Plasma Proteins Plasma-derived therapeutic proteins including albumin and other blood products manufactured for medical use by hospitals, healthcare providers, and government health programs.
• Biosimilars Portfolio Development and manufacturing of biosimilar medications including monoclonal antibodies, growth factors, and other biologics for cancer, autoimmune diseases, and other therapeutic areas.
• Specialty Pharmaceuticals Specialty pharmaceutical products including novel drug formulations and specialty injectable therapies such as MIRel (Reteplase), Relipoietin (Erythropoietin), and Reliseal (Fibrin Sealant).
• Clinical Research Services Comprehensive clinical development services for molecules including Phase I-IV trials, bioequivalence studies, and regulatory support provided to pharmaceutical companies.
• Regenerative Medicine / Cell Therapies Novel cell therapies and stem cell-based treatments for regenerative medicine applications.
• Cord Blood Repository Stem cell banking services through cord blood collection, processing, and long-term storage for families seeking preservation for potential future therapeutic use.
• Diagnostics (SMART Diagnostics) High-end DNA-based diagnostic testing and molecular medicine research services (branded as SMART Diagnostics), including RT-PCR Covid-19 testing approved by ICMR.
• Covid-19 RT-PCR Testing RT-PCR based Covid-19 testing service using detection of unique sequences of viral RNA in nasopharyngeal or oropharyngeal samples, approved by the Indian Council of Medical Research (ICMR).

Quantifiable outcome

• 100% concordance in inter-laboratory validation of COVID-19 test results with approved laboratories

Named customers3 records

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered minor, core and major.

• JSS Academy of Higher Education and Research (JSS AHER)minorStrategic or Co-development Partner · 23 April 2026Joint organization of international workshop on generic medicines. Dr. Bobby George, Vice President of Reliance Life Sciences, served as chief guest at the workshop covering themes including future of generic drug development, manufacturing excellence, bioequivalence, safety, global regulatory pathways, intellectual property rights, and societal impacts.
• NAM S&T Centre, New DelhiminorStrategic or Co-development Partner · 23 April 2026Joint organization of international workshop on generic medicines with JSS AHER and IACP. NAM S&T Centre contributed to workshop covering future of generic drug development and global regulatory pathways.
• Indian Association of Colleges of Pharmacy (IACP), ChennaiminorStrategic or Co-development Partner · 23 April 2026Joint organization of international workshop on generic medicines with JSS AHER and NAM S&T Centre covering pharmaceutical industry themes.
• CiplacoreStrategic or Co-development Partner · 19 March 2026Cooperation between Belarusian state enterprise Academpharm and Indian pharmaceutical manufacturers Cipla and Reliance Life Sciences for pharmaceutical research, registration dossiers under EAEU rules, production technologies through pilot batches, clinical trials, and validation of new testing methods for substances and finished dosage forms.
• Sri Lanka GovernmentmajorChannel Partner/ Reseller/ Distributor · 1 August 2015Tie-up with Sri Lanka government to manufacture plasma proteins from blood. Sri Lankan cabinet approved the partnership with Reliance Life Sciences for domestic plasma protein production to address albumin shortages.
• Torrent PharmamajorChannel Partner/ Reseller/ Distributor · 1 December 2014Licensing agreement for three biosimilars. Torrent Pharma acquired rights to market three biosimilar products developed by Reliance Life Sciences in the Indian market. Multiple media reports confirm the partnership covering distribution of biosimilar products.
• Genemedix Plc, UKcoreStrategic or Co-development Partner · 7 February 2007Acquisition of Genemedix Plc, UK by Reliance Life Sciences to expand presence in the UK and European markets and strengthen biosimilar development capabilities.

Scale indicators6 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Celltrion: South Korea-based global biosimilars leader with approved products in infliximab, trastuzumab, rituximab, adalimumab, and bevacizumab across the US, EU, and Asia. Comparable as a pure-play biosimilar developer with deep clinical research capabilities and a global regulatory footprint that Reliance Life Sciences is seeking to emulate.
• Dr. Reddy's Laboratories: Indian multinational pharma with biologics and biosimilars in oncology and immunology, plus proprietary and generic small molecules. Directly comparable across biosimilar portfolio, US FDA-approved manufacturing, pan-India commercial scale, and emerging-market export strategy.
• Aurobindo Pharma: Large Indian generics and specialty pharma company expanding into biosimilars and complex injectables. Comparable as an Indian-headquartered, vertically integrated pharma with US FDA-approved facilities and a growing biologics franchise.
• Zydus Cadila: Indian pharmaceutical company with a developed biosimilars pipeline and approved products in oncology, autoimmune, and supportive care. Comparable to Reliance Life Sciences across biosimilar development capabilities, integrated manufacturing, and Indian distribution depth.
• Samsung Bioepis: South Korean biosimilar developer (now jointly owned by Samsung and Biocon) with approved products in oncology, immunology, and ophthalmology across regulated markets. Comparable in biosimilar pipeline depth, clinical research execution, and emerging-to-regulated market commercial sequencing.
• Viatris (Mylan): Global pharma with a substantial biosimilars portfolio inherited from Mylan (including insulin, oncology biosimilars, and immunology products). Comparable across global biosimilar commercialization, US FDA-registered manufacturing network, and broad emerging-market distribution.
• Intas Pharmaceuticals: Indian pharmaceutical company with a substantial biosimilars portfolio (including Accentrix/ranibizumab and oncology biosimilars) and global commercial reach through its Accord Healthcare subsidiary. Closely comparable in biosimilar product mix, India-based manufacturing, and emerging-market commercial model.
• Biocon Biologics: India's largest pure-play biosimilars company with approved products in trastuzumab, bevacizumab, adalimumab, pegfilgrastim, insulin glargine, and rh-insulin across global regulated and emerging markets. Directly comparable to Reliance Life Sciences in oncology and immunology biosimilars, vertically integrated manufacturing, and clinical research capabilities.
• Lupin Pharmaceuticals: Indian multinational pharma with a developing biosimilars and complex injectables portfolio alongside generics. Comparable across Indian-headquartered integrated pharma, US FDA-approved manufacturing, and emerging presence in specialty/biologic therapeutic categories.

Broad incumbents

• Amgen: Global originator biologics leader that has also invested in biosimilars (with Allergan) and remains the reference product manufacturer against which biosimilar developers like Reliance Life Sciences benchmark clinical comparability. Relevant as the originator competitor and benchmark for biosimilar regulatory pathway strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Reliance Life Sciences